A unique CD4+ large granular lymphocytosis occurring in patients treated with tumor necrosis factor α inhibitors: report of 2 cases

Hum Pathol. 2015 Aug;46(8):1237-41. doi: 10.1016/j.humpath.2015.04.015. Epub 2015 May 13.

Abstract

We report 2 cases of CD4(+) large granular lymphocyte (LGL) lymphocytosis occurring in patients being treated with a monoclonal antibody against tumor necrosis factor α for underlying autoimmune disorders. CD4(+) LGL lymphocytosis is a rare subset of LGL disease that has previously only been described in patients without underlying autoimmune disorders, and most demonstrate uniform coexpression of CD56 on the atypical T cells. The clinical features, with both cases occurring in patients with autoimmune disease, and immunophenotypic features, with both cases showing dim CD8 coexpression without CD56 in the CD4(+) LGLs, suggest that the reported cases are distinct from those previously described and may represent a novel T-cell LGL lymphocytosis emerging from iatrogenic immune modulation of patients with underlying autoimmune disorders.

Keywords: Adalimumab; CD4; LGL; Large granular lymphocytosis; T cell; Tumor necrosis factor α.

Publication types

  • Case Reports

MeSH terms

  • Adalimumab
  • Aged
  • Antibodies, Monoclonal, Humanized / adverse effects*
  • Antirheumatic Agents / adverse effects*
  • Arthralgia / drug therapy
  • Arthritis, Rheumatoid / drug therapy
  • CD4-Positive T-Lymphocytes / pathology*
  • Female
  • Flow Cytometry
  • Humans
  • Immunophenotyping
  • Lymphocytosis / chemically induced*
  • Male
  • Middle Aged
  • Spondylarthropathies / drug therapy
  • Tumor Necrosis Factor-alpha / antagonists & inhibitors

Substances

  • Antibodies, Monoclonal, Humanized
  • Antirheumatic Agents
  • Tumor Necrosis Factor-alpha
  • Adalimumab